EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patient Preferences for Self-Administered Subcutaneous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy

Batyrkhan Kuatov, Sarah-Jane Cashmore, Noemi Hahn, Julia Braverman, Laurence Undreiner, Shicheng Weng, Ben Gibbons

Neurology and Therapy · 30.10.2026

DOI: 10.1007/s40120-026-01062-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 30.10.2026. Verfasst von Batyrkhan Kuatov und 6 weiteren Autor:innen. Beteiligte Einrichtung: CSL Behring, Bern, Switzerland. batyrkhan.kuatov@cslbehring.com. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Behring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Subcutaneous immunoglobulin (SCIG) therapy is increasingly used to treat chronic inflammatory demyelinating polyneuropathy (CIDP). To support patient-centered care and improve adherence, we evaluated which SCIG treatment attributes matter most to patients and compared experiences using pre-filled syringes (PFS) versus vials.

Methods

A conjoint analysis was conducted with n = 187 Ig-using patients with CIDP from the USA and Canada to quantify the relative importance of attributes related to self-administered subcutaneous therapy. Following this, a survey of n = 68 SCIG users assessed real-world experiences and preferences with PFS and vial-based administration, including outcomes among patients with CIDP who switched to PFS.

Results

The main drivers of preference in subcutaneous therapies were ease of preparation (31% of relative importance) and likelihood of getting sick after infusion (27% of relative importance). Injection volume and skin reaction ranked third (23% of relative importance). In the survey, PFS users reported that administering their infusions was more convenient (7-point scale, median 6 vs median 5, respectively) and they were more confident administering their infusions than vial users (completely or very confident, 98% vs 84%, respectively). More PFS users reported feeling “better than usual” within the first day post-infusion compared with vial users (51% vs 20%, respectively). Among patients who switched from vials to PFS ( n = 17), 71% reported higher treatment satisfaction, 82% found PFS more convenient, and 65% reported faster administration with PFS.

Conclusions

PFS aligns with key preference drivers for self-administered SCIG therapy in CIDP compared to vials. These findings highlight the value of integrating patient-prioritized treatment attributes and preferences into clinical decision-making.

Schlagwörter

Stichwörter der Autor:innen

Immunoglobulin therapyInfusion burdenPre-filled syringeQuality of lifeSCIGSubcutaneous

Autor:innen und Institutionen

  • CSL Behring, Bern, Switzerland. batyrkhan.kuatov@cslbehring.com.
  • Bryter Inc., New York, NY, USA.
  • CSL Behring, Waltham, MA, USA.
  • CSL Behring, Paris, France.

Förderung

  • CSL Behring

Zitieren

APA

Kuatov, B., Cashmore, S. J., Hahn, N., Braverman, J., Undreiner, L., Weng, S., & Gibbons, B. (2026). Patient Preferences for Self-Administered Subcutaneous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. Neurology and Therapy. https://doi.org/10.1007/s40120-026-01062-3

Vancouver

Kuatov B, Cashmore SJ, Hahn N, Braverman J, Undreiner L, Weng S, et al. Patient Preferences for Self-Administered Subcutaneous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. Neurology and Therapy. 2026. doi:10.1007/s40120-026-01062-3

BibTeX
@article{Kuatov2026,
  author = {Kuatov, Batyrkhan and Cashmore, Sarah-Jane and Hahn, Noemi and Braverman, Julia and Undreiner, Laurence and Weng, Shicheng and Gibbons, Ben},
  title = {Patient Preferences for Self-Administered Subcutaneous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy},
  journal = {Neurology and Therapy},
  year = {2026},
  doi = {10.1007/s40120-026-01062-3}
}
Kostenlos starten →